Our findings suggest that CKS2‐shRNA may serve as a sensitizer to enhance the sensitivity of tumor cells to chemotherapy drugs, providing experimental evidence for potential clinical applications in BL and DLBCL. This evidence concerns the gene CKS2 and Burkitt lymphoma.